Accéder au contenu
Merck

Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis.

PLoS pathogens (2022-06-22)
Bryan A Johnson, Yiyang Zhou, Kumari G Lokugamage, Michelle N Vu, Nathen Bopp, Patricia A Crocquet-Valdes, Birte Kalveram, Craig Schindewolf, Yang Liu, Dionna Scharton, Jessica A Plante, Xuping Xie, Patricia Aguilar, Scott C Weaver, Pei-Yong Shi, David H Walker, Andrew L Routh, Kenneth S Plante, Vineet D Menachery
RÉSUMÉ

While SARS-CoV-2 continues to adapt for human infection and transmission, genetic variation outside of the spike gene remains largely unexplored. This study investigates a highly variable region at residues 203-205 in the SARS-CoV-2 nucleocapsid protein. Recreating a mutation found in the alpha and omicron variants in an early pandemic (WA-1) background, we find that the R203K+G204R mutation is sufficient to enhance replication, fitness, and pathogenesis of SARS-CoV-2. The R203K+G204R mutant corresponds with increased viral RNA and protein both in vitro and in vivo. Importantly, the R203K+G204R mutation increases nucleocapsid phosphorylation and confers resistance to inhibition of the GSK-3 kinase, providing a molecular basis for increased virus replication. Notably, analogous alanine substitutions at positions 203+204 also increase SARS-CoV-2 replication and augment phosphorylation, suggesting that infection is enhanced through ablation of the ancestral 'RG' motif. Overall, these results demonstrate that variant mutations outside spike are key components in SARS-CoV-2's continued adaptation to human infection.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Kenpaullone, A potent, cell-permeable, and reversible inhibitor of glycogen synthase kinase-3β (IC₅₀ = 230 nM), Lck (IC₅₀ = 470 nM), and cyclin-dependent kinases (Cdks).